Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. - Test2 - elhamkhani - TriplyDB

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

http://www.wikidata.org/entity/Q37684589

about

The NCI-60 Methylome and Its Integration into CellMiner.Drugging the Cancers Addicted to DNA Repair.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Unravelling the biology of SCLC: implications for therapy.Targeting DNA repair and replication stress in the treatment of ovarian cancer.Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.Relevance of genetic alterations in squamous and small cell lung cancer.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.Target engagement imaging of PARP inhibitors in small-cell lung cancer.Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors.SLFN11 Blocks Stressed Replication Forks Independently of ATR.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy

P2860

Q30490461-EE184E9E-6C6D-4D72-9850-FF4491932FD6 Q33702497-00060371-5099-4FD7-B118-766C4ED8B6F0 Q37607283-2A0FC6B3-99CC-4BE6-ABBF-1569753AD40B Q38769421-1C7BDA90-D970-45FE-9908-2A4C4BB762B8 Q39393235-AD1083EF-827C-4B86-B764-53F72FD1CB7E Q42223681-28D11256-074F-491C-B2C5-BD461F2DD511 Q42315217-C53FBF2E-A7D0-4DD8-9E09-FAC04D0DCEEF Q44483486-C91B2043-D3E0-49AE-A3AE-B472CE62072D Q47130816-0FC063A4-5939-48EF-841F-F545E0B1DEDB Q48251246-D6D4DFD9-2E7C-4853-B6AC-BFE13D40F535 Q48290610-57C65648-A0CC-4926-ABD6-D1159B429630 Q49390599-06B6C4F4-290C-4622-A145-B8886725EF22 Q50209876-06B91288-6658-48BE-B720-A18A6E5D33F1 Q52596087-C03B4879-B9CC-471F-99D9-D210477710A4 Q52657032-D4CC7094-61BF-4298-9AD7-D2305897512E Q55211683-67384C52-214C-494A-90D6-1B83DBFBFCC4 Q57176137-D9AFB6A3-5D3D-40E0-A92B-B5CD20E8DD41 Q58719363-2453E1E6-7A3D-44CF-A6AB-624DDB189F57

P2860

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

http://www.wikidata.org/entity/Q37684589

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@en

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@nl

type

label

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@en

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@nl

prefLabel

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@en

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@nl

P1433

Q37684589-9D5BB701-403D-4A2D-B96D-8E6C67D316D2

P1476

Q37684589-8196451A-C74C-438D-B6D2-F9EC1260C4E4

P2093

Q37684589-0118B4C0-00C6-4C78-A173-8511D985D0CB

Q37684589-32DE32F4-D169-478D-A904-C9DE9A436F15

Q37684589-4DF4B10A-EF90-40C3-9B27-D0FB7CFAD929

Q37684589-B27A5D62-71AB-4184-9A01-DB4594C15D26

Q37684589-DFDD63F8-E56E-4FA8-9606-5FC8C966F721

Q37684589-FFAC2C49-F11B-4816-8034-3EAAF5EBC568

P2860

Q37684589-236B5EE2-3DEC-4392-ADC8-321C992C6663

Q37684589-281AE2D6-4B15-4F3F-827C-5620F42B6C28

Q37684589-2ECD64E3-E62D-4C92-A604-5DBD65C53EF7

Q37684589-31FE512E-075C-4AC9-9818-5BBFE8DA8588

Q37684589-38DB4A86-A6D7-411F-841D-6735601E912F

Q37684589-3E7B12D6-76B2-4C77-A0F6-509098E3E2D3

Q37684589-4381489C-B434-43BA-BB8D-3A05D2E612D6

Q37684589-459DE3E4-3819-48F0-9692-24AA12683049

Q37684589-4770451A-C815-45BB-BB66-8DA1D014D7A3

Q37684589-4A20DC8E-31DB-443C-9639-812857DE7B4F

P304

Q37684589-CA716784-29F3-4A14-B20E-AB8BB7E508F7

P31

Q37684589-264A4066-BF56-4ADA-98F2-8875F7179755

P356

Q37684589-78561011-40FB-4334-B60B-7C1259A1965B

P407

Q37684589-47225929-CE40-4D8D-A0CA-B83579E932E6

P433

Q37684589-587E889C-488D-4C06-B293-EE52A1AFD544

P478

Q37684589-CCC72253-AC72-4338-9DBB-C2EB71904551

P50

Q37684589-3B60D71A-E26F-427F-B056-361E1228F9B9

P577

Q37684589-AF2F0695-CAB2-44EF-B57B-6FEC4F005795

P698

Q37684589-BCC1AF38-614A-41AD-8CE7-6DAEC35331FE

P932

Q37684589-5493D14C-249A-4ADF-B3AE-60219D8D5F27

P356

ONCOTARGET.12266

P1433

P1476

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

@en

P2093

Guoying K Yu

http://www.w3.org/2001/XMLSchema#string

Junko Murai

http://www.w3.org/2001/XMLSchema#string

Sai-Wen Tang

http://www.w3.org/2001/XMLSchema#string

Ying Feng

http://www.w3.org/2001/XMLSchema#string

Yuanbin Ru

http://www.w3.org/2001/XMLSchema#string

Yuqiao Shen

http://www.w3.org/2001/XMLSchema#string

P2860

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

Multiplex genome engineering using CRISPR/Cas systems

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Targeting the DNA Damage Response in Cancer

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Systematic identification of genomic markers of drug sensitivity in cancer cells

P304

76534-76550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12266

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27708213

http://www.w3.org/2001/XMLSchema#string

P932

5340226

http://www.w3.org/2001/XMLSchema#string